TERN logo

TERN
Terns Pharmaceuticals Inc

2,277
Mkt Cap
$6.12B
Volume
6.35M
52W High
$53.19
52W Low
$2.75
PE Ratio
-51.28
TERN Fundamentals
Price
$52.95
Prev Close
$52.93
Open
$52.97
50D MA
$51.03
Beta
0.98
Avg. Volume
6.79M
EPS (Annual)
-$1.03
P/B
5.91
Rev/Employee
$0.00
$2,745.87
Loading...
Loading...
News
all
press releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (Terns) (Nasdaq: TERN). The Terns acquisition reflects Mercks continued focus on sciencedriven, valueenhancing business development...
News Placeholder
More News
News Placeholder
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from Analysts
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommen...
News Placeholder
MRK Q1 Earnings & Sales Beat Estimates, 2026 Sales View Tightened
Merck tops Q1 estimates as Keytruda drives growth and lifts 2026 EPS outlook despite acquisition charge. Sales view tightened.
News Placeholder
Pictet Asset Management Holding SA Boosts Stake in Terns Pharmaceuticals, Inc. $TERN
Pictet Asset Management Holding SA lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 42.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,577...
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) Earns Market Perform Rating from Oppenheimer
Oppenheimer restated a "market perform" rating and set a $58.00 target price on shares of Terns Pharmaceuticals in a research report on Monday...
News Placeholder
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
Merck heads into Q1 with strong Keytruda demand but rising pressure from generics, vaccines slump, and deal costs persist. Can it retain growth momentum?
News Placeholder
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in...
News Placeholder
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?
Merck stock up 11% YTD as Keytruda growth, pipeline gains and M&A lift outlook, but patent risks, Gardasil slump and generics weigh on near-term upside.
News Placeholder
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 15, 2026 Insiders may stand to receive...
News Placeholder
Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. boosted their price target on Terns Pharmaceuticals from $44.00 to $44.50 and gave the stock an "overweight" rating in a research report on Tuesday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available